SE513313C2 - Modifierad interferonproduktion - Google Patents

Modifierad interferonproduktion

Info

Publication number: SE513313C2
Authority: SE; Sweden
Prior art keywords: interferon; methyl; pyrrolidinone; production; leukocytes
Prior art date: 1998-12-29

Application number

SE9804583A

Other languages

English (en)

Swedish (sv)

Other versions

SE9804583L (sv

SE9804583D0 (sv

Inventor

Aasa Berglund

Original Assignee

Bionative Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-29

Filing date

1998-12-29

Publication date

2000-08-21

1998-12-29 Application filed by Bionative Ab filed Critical Bionative Ab

1998-12-29 Priority to SE9804583A priority Critical patent/SE513313C2/sv

1998-12-29 Publication of SE9804583D0 publication Critical patent/SE9804583D0/xx

1999-12-22 Priority to EP99965674A priority patent/EP1141012B1/de

1999-12-22 Priority to PCT/SE1999/002446 priority patent/WO2000039163A1/en

1999-12-22 Priority to US09/869,269 priority patent/US6962695B1/en

1999-12-22 Priority to AT99965674T priority patent/ATE298766T1/de

1999-12-22 Priority to ES99965674T priority patent/ES2244239T3/es

1999-12-22 Priority to DE69926013T priority patent/DE69926013T2/de

1999-12-22 Priority to AU21362/00A priority patent/AU2136200A/en

1999-12-22 Priority to HU0104761A priority patent/HU227164B1/hu

1999-12-22 Priority to CA2354025A priority patent/CA2354025C/en

1999-12-22 Priority to HK02101764.0A priority patent/HK1040086B/en

1999-12-22 Priority to PT99965674T priority patent/PT1141012E/pt

1999-12-22 Priority to JP2000591074A priority patent/JP4584456B2/ja

1999-12-22 Priority to CZ20011951A priority patent/CZ301888B6/cs

2000-06-30 Publication of SE9804583L publication Critical patent/SE9804583L/

2000-08-21 Publication of SE513313C2 publication Critical patent/SE513313C2/sv

2001-06-28 Priority to NO20013243A priority patent/NO328424B1/no

Links

230000016396 cytokine production Effects 0.000 title description 7
210000000265 leukocyte Anatomy 0.000 claims abstract description 42
238000004519 manufacturing process Methods 0.000 claims abstract description 35
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 32
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims abstract description 32
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims abstract description 24
239000003960 organic solvent Substances 0.000 claims abstract description 22
241000700605 Viruses Species 0.000 claims abstract description 20
238000000034 method Methods 0.000 claims abstract description 17
229960000278 theophylline Drugs 0.000 claims abstract description 16
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims abstract description 12
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 8
125000001931 aliphatic group Chemical group 0.000 claims abstract description 8
150000001875 compounds Chemical class 0.000 claims abstract description 7
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims abstract description 6
229940113082 thymine Drugs 0.000 claims abstract description 6
-1 cyclic sulfoxides Chemical class 0.000 claims abstract description 5
CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 claims abstract description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims abstract description 4
ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical class OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 claims abstract description 4
150000008431 aliphatic amides Chemical class 0.000 claims abstract description 4
150000008365 aromatic ketones Chemical class 0.000 claims abstract description 4
150000003950 cyclic amides Chemical class 0.000 claims abstract description 4
230000001939 inductive effect Effects 0.000 claims abstract description 4
ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 claims abstract description 4
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims abstract description 3
ADLWOFHKMXUDKF-UHFFFAOYSA-N 2-amino-5-bromo-6-methyl-1h-pyrimidin-4-one Chemical compound CC=1NC(N)=NC(=O)C=1Br ADLWOFHKMXUDKF-UHFFFAOYSA-N 0.000 claims description 20
241000711408 Murine respirovirus Species 0.000 claims description 18
229940079322 interferon Drugs 0.000 claims description 16
230000006698 induction Effects 0.000 claims description 10
239000012744 reinforcing agent Substances 0.000 claims description 9
239000002904 solvent Substances 0.000 claims description 7
ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 claims description 3
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 3
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 3
210000001616 monocyte Anatomy 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 abstract description 3
230000002708 enhancing effect Effects 0.000 abstract description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 abstract 2
NPGFWOWMRXCXKF-UHFFFAOYSA-N 1-ethylpyrrolidin-2-one;4-methylpentan-2-one Chemical compound CC(C)CC(C)=O.CCN1CCCC1=O NPGFWOWMRXCXKF-UHFFFAOYSA-N 0.000 abstract 1
YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 abstract 1
229940075420 xanthine Drugs 0.000 abstract 1
108010047761 Interferon-alpha Proteins 0.000 description 50
102000006992 Interferon-alpha Human genes 0.000 description 50
210000004027 cell Anatomy 0.000 description 49
238000011534 incubation Methods 0.000 description 19
238000007792 addition Methods 0.000 description 18
230000000694 effects Effects 0.000 description 13
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 12
239000003623 enhancer Substances 0.000 description 12
239000000126 substance Substances 0.000 description 11
239000002609 medium Substances 0.000 description 10
102000014150 Interferons Human genes 0.000 description 9
108010050904 Interferons Proteins 0.000 description 9
239000000411 inducer Substances 0.000 description 9
238000001727 in vivo Methods 0.000 description 8
150000003230 pyrimidines Chemical class 0.000 description 7
238000002474 experimental method Methods 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
239000006145 Eagle's minimal essential medium Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000007640 basal medium Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 2
230000037452 priming Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
230000003014 reinforcing effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
108010078049 Interferon alpha-2 Proteins 0.000 description 1
102100039350 Interferon alpha-7 Human genes 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
108010022337 Leucine Enkephalin Proteins 0.000 description 1
240000006240 Linum usitatissimum Species 0.000 description 1
235000004431 Linum usitatissimum Nutrition 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
102100024622 Proenkephalin-B Human genes 0.000 description 1
244000292604 Salvia columbariae Species 0.000 description 1
235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
235000001498 Salvia hispanica Nutrition 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
150000004056 anthraquinones Chemical class 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
235000014167 chia Nutrition 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000004544 dc2 Anatomy 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000003067 hemagglutinative effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000002799 interferon inducing agent Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
229940064914 retrovir Drugs 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
229960002324 trifluoperazine Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Steroid Compounds (AREA)

SE9804583A 1998-12-29 1998-12-29 Modifierad interferonproduktion SE513313C2 (sv)

Priority Applications (15)

Application Number	Priority Date	Filing Date	Title
SE9804583A SE513313C2 (sv)	1998-12-29	1998-12-29	Modifierad interferonproduktion
CZ20011951A CZ301888B6 (cs)	1998-12-29	1999-12-22	Zpusob výroby alfa-interferonu
DE69926013T DE69926013T2 (de)	1998-12-29	1999-12-22	Veränderung der herstellung von alpha-interferon
HU0104761A HU227164B1 (en)	1998-12-29	1999-12-22	Modification of interferon alpha production
US09/869,269 US6962695B1 (en)	1998-12-29	1999-12-22	Modification of interferon alpha production
AT99965674T ATE298766T1 (de)	1998-12-29	1999-12-22	Veränderung der herstellung von alpha-interferon
ES99965674T ES2244239T3 (es)	1998-12-29	1999-12-22	Modificacion de la produccion de interferon alfa.
EP99965674A EP1141012B1 (de)	1998-12-29	1999-12-22	Veränderung der herstellung von alpha-interferon
AU21362/00A AU2136200A (en)	1998-12-29	1999-12-22	Modification of interferon alpha production
PCT/SE1999/002446 WO2000039163A1 (en)	1998-12-29	1999-12-22	Modification of interferon alpha production
CA2354025A CA2354025C (en)	1998-12-29	1999-12-22	Modification of interferon alpha production
HK02101764.0A HK1040086B (en)	1998-12-29	1999-12-22	Modification of interferon alpha production
PT99965674T PT1141012E (pt)	1998-12-29	1999-12-22	Modificacao na producao de alfa interferao
JP2000591074A JP4584456B2 (ja)	1998-12-29	1999-12-22	インターフェロンαの製造の改良
NO20013243A NO328424B1 (no)	1998-12-29	2001-06-28	Fremgangsmate for fremstilling in vitro av alfa-interferon

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9804583A SE513313C2 (sv)	1998-12-29	1998-12-29	Modifierad interferonproduktion

Publications (3)

Publication Number	Publication Date
SE9804583D0 SE9804583D0 (sv)	1998-12-29
SE9804583L SE9804583L (sv)	2000-06-30
SE513313C2 true SE513313C2 (sv)	2000-08-21

Family

ID=20413894

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9804583A SE513313C2 (sv)	1998-12-29	1998-12-29	Modifierad interferonproduktion

Country Status (15)

Country	Link
US (1)	US6962695B1 (de)
EP (1)	EP1141012B1 (de)
JP (1)	JP4584456B2 (de)
AT (1)	ATE298766T1 (de)
AU (1)	AU2136200A (de)
CA (1)	CA2354025C (de)
CZ (1)	CZ301888B6 (de)
DE (1)	DE69926013T2 (de)
ES (1)	ES2244239T3 (de)
HK (1)	HK1040086B (de)
HU (1)	HU227164B1 (de)
NO (1)	NO328424B1 (de)
PT (1)	PT1141012E (de)
SE (1)	SE513313C2 (de)
WO (1)	WO2000039163A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE513313C2 (sv) *	1998-12-29	2000-08-21	Bionative Ab	Modifierad interferonproduktion
JP2009298752A (ja) *	2008-06-17	2009-12-24	Shiseido Co Ltd	皮膚外用剤組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3932617A (en) *	1974-05-24	1976-01-13	The Upjohn Company	Interferon induction
US4027021A (en)	1974-08-23	1977-05-31	The Upjohn Company	Interferon induction
CS215108B2 (en)	1977-07-15	1982-07-30	Wellcome Found	Method of making the interferrone
EP0005476B1 (de)	1978-05-17	1981-12-30	Dr. Karl Thomae GmbH	Verfahren zur Herstellung von Humaninterferon
JPS56135420A (en) *	1980-03-26	1981-10-22	Fumiaki Taguchi	Suppressive substance of virus and its preparation
IT1172270B (it) *	1982-06-21	1987-06-18	Wellcome Found	Procedimento per la produzione di interferon
SE513313C2 (sv) *	1998-12-29	2000-08-21	Bionative Ab	Modifierad interferonproduktion

1998
- 1998-12-29 SE SE9804583A patent/SE513313C2/sv not_active IP Right Cessation
1999
- 1999-12-22 AT AT99965674T patent/ATE298766T1/de active
- 1999-12-22 CZ CZ20011951A patent/CZ301888B6/cs not_active IP Right Cessation
- 1999-12-22 AU AU21362/00A patent/AU2136200A/en not_active Abandoned
- 1999-12-22 EP EP99965674A patent/EP1141012B1/de not_active Expired - Lifetime
- 1999-12-22 WO PCT/SE1999/002446 patent/WO2000039163A1/en not_active Ceased
- 1999-12-22 PT PT99965674T patent/PT1141012E/pt unknown
- 1999-12-22 US US09/869,269 patent/US6962695B1/en not_active Expired - Fee Related
- 1999-12-22 CA CA2354025A patent/CA2354025C/en not_active Expired - Fee Related
- 1999-12-22 JP JP2000591074A patent/JP4584456B2/ja not_active Expired - Fee Related
- 1999-12-22 DE DE69926013T patent/DE69926013T2/de not_active Expired - Lifetime
- 1999-12-22 HU HU0104761A patent/HU227164B1/hu not_active IP Right Cessation
- 1999-12-22 HK HK02101764.0A patent/HK1040086B/en not_active IP Right Cessation
- 1999-12-22 ES ES99965674T patent/ES2244239T3/es not_active Expired - Lifetime
2001
- 2001-06-28 NO NO20013243A patent/NO328424B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP0104761A2 (hu)	2002-04-29
JP2002533112A (ja)	2002-10-08
CA2354025A1 (en)	2000-07-06
EP1141012A1 (de)	2001-10-10
CA2354025C (en)	2012-05-22
DE69926013D1 (de)	2005-08-04
SE9804583L (sv)	2000-06-30
AU2136200A (en)	2000-07-31
WO2000039163A1 (en)	2000-07-06
EP1141012B1 (de)	2005-06-29
DE69926013T2 (de)	2006-05-18
NO328424B1 (no)	2010-02-15
HK1040086B (en)	2006-01-20
JP4584456B2 (ja)	2010-11-24
HU227164B1 (en)	2010-09-28
HK1040086A1 (en)	2002-05-24
ES2244239T3 (es)	2005-12-01
ATE298766T1 (de)	2005-07-15
US6962695B1 (en)	2005-11-08
CZ20011951A3 (cs)	2002-02-13
HUP0104761A3 (en)	2004-07-28
NO20013243D0 (no)	2001-06-28
NO20013243L (no)	2001-06-28
SE9804583D0 (sv)	1998-12-29
PT1141012E (pt)	2006-06-30
CZ301888B6 (cs)	2010-07-21

Legal Events

Date	Code	Title	Description
2007-08-21	NUG	Patent has lapsed

Publication	Publication Date	Title
Derynck et al.	1980	Isolation and structure of a human fibroblast interferon gene
US4738845A (en)	1988-04-19	Modified (115-145) beta interferons
DK163187B (da)	1992-02-03	Fremgangsmaader til fremstilling af humant immuninterferon (gamma-interferon) samt dna-fragmenter, rekombinante klonings- og udtrykkelsesvektorer og rekombinante mikroorganismer og cellekulturer til anvendelse herved
EP0963437B1 (de)	2005-10-26	Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
Dukema et al.	1986	[63] Cloning, expression, and purification of rat IFN-γ
EP1694703B1 (de)	2011-08-31	Verfahren zur aufreinigung von interferon-beta
KR20010073658A (ko)	2001-08-01	인간 인터페론 알파의 발현 분비벡터 및 이를 이용한인터페론 알파의 생산 방법
SE513313C2 (sv)	2000-08-21	Modifierad interferonproduktion
EP1697411B1 (de)	2011-08-24	Verfahren zur aufreinigung von interferon-beta
Carvalho et al.	1998	Culture of human amniotic cells: a system to study interferon production
WO2006099701A1 (en)	2006-09-28	Inhibitor of endogenous human interferon - gamma
White et al.	1980	Large-scale production of human interferons
Testa	1997	Distribution of Interferon-α2 Genes in Humans
Du Pont	2012	Wilmington, Delaware 19898